Tech Update: A new approach to Alzheimer’s and proof that video calls are exhausting
Small Canadian biotech start-up Treventis is playing in the big leagues. The Toronto company just secured a partnership with Takeda, Japan’s largest drug maker, to help develop a new therapy for Alzheimer’s. There’s still uncertainty around the causes of Alzheimer’s, but misfolding of a protein called tau is thought to play an important role. It is believed […]
The Pharma Letter: Takeda partners with Treventis on Alzheimer’s disease research
Japan’s largest drugmaker Takeda (TYO: 4502) has linked up with little-known Canadian biotech Treventis for the further research, development, and commercialization of small molecules that target tau, a key protein in Alzheimer’s disease (AD). This therapeutic strategy aims to markedly reduce tau misfolding and is a potential disease-modifying mechanism in AD as well as in […]
UHN: Takeda licenses small molecule developed by researchers at UHN’s Krembil Brain Institute, targeting tau protein implicated in Alzheimer’s disease
(Toronto, April 11, 2023) – As announced today in a press release by biotechnology company Treventis, global pharmaceutical company Takeda has agreed to exclusively license a group of small molecules that target tau – a protein in which misfolding and aggregation are believed to be a cause of Alzheimer’s disease. The molecules were developed by […]
Endpoints News: Takeda joins forces with small private biotech for preclinical Alzheimer’s research
Takeda is wading deeper into Alzheimer’s disease research with a new preclinical collaboration announced Tuesday. The company will work with Treventis, a little-known private biotech from Toronto, on a small molecule program targeting the tau protein. Treventis CEO Christopher Barden tells Endpoints News the biotech is still working on selecting which drug candidate to move […]
Treventis Partners its Preclinical Program in Alzheimer’s Disease with Takeda
April 11, 2023 – Toronto, Ontario, Canada – Treventis Corporation, a privately held biotechnology company, announced today that it has entered an option, collaboration, and license agreement with Takeda for the further research, development, and commercialization of small molecules that target tau, a key protein in Alzheimer’s Disease (AD). This therapeutic strategy aims to markedly […]
Treventis Awarded $2.97M Grant from the U.S. Department of Defense
Funds for Development of a Drug Against Neurodegenerative Diseases October 18, 2022 BERNVILLE, Pennsylvania – Treventis Corporation, a privately held biotechnology company, announced today that their proposal to preclinically develop a small molecule misfolding drug for frontotemporal dementia, has been awarded funding totaling $2,977,166 by the Congressionally Directed Medical Research Programs (CDMRP), part of the […]
Treventis founder Sultan Darvesh awarded Jubilee Medal
Treventis is pleased to congratulate our founder Dr. Sultan Darvesh, neurologist and Dalhousie professor, for being one of the first 70 Nova Scotian recipients of the Platinum Jubilee Medal. This award was established by the Government of Nova Scotia in recognition of Queen Elizabeth II’s 70th anniversary of accession to the throne. Dr. Darvesh received […]
Treventis founders give invited lectures at WATOC
Treventis founders Donald Weaver and Christopher Barden are both invited speakers at the 12th Triennial Congress of the World Association of Theoretical and Computational Chemists (WATOC), which was rescheduled from summer 2020 due to the COVID-19 pandemic. Dr. Barden will be speaking on Monday July 4 about “Computer-aided Design of Small Molecule Inhibitors of Oligomerization […]
Dr. Donald Weaver, Oskar Fischer Prize Winner
Congratulations to our own Dr. Donald Weaver, Treventis founder and Chief Medical Officer, for being an Oskar Fischer Prize winner! Don will receive a Silver prize award later this month at the University of Texas at San Antonio, for his innovative approach to Alzheimer’s research. So proud! Read More
Treventis Attending BIO 2022
Treventis will be at BIO next week -in person! Please ping us if you would like to meet in person or virtually. https://www.linkedin.com/in/chrisbarden/